SAMAR CCC

(Name)
(University)
Executive summary

 Biosantee wants to launch SAMAR CCC
 This antimicrobial resistance medicine is a replacement to antibiotics
 SAMAR CCC has to pass all the four phases of FDA approval
 Its target market is in North America
 Projected profits is US$ 2 billion for the first 2 years
Description of business

 Biosantee is a private company located in Trenton, New Jersey
 It deals with antibiotics and has been in operation for more than 20 years
 It adopts a sophisticated five-phase business model
Mission & Vision

 Mission
 To be the world’s most acknowledgeable and well committed company to its
patients, customers, colleagues, investors, business partners, and communities
where it delivers its services
 Vision
 Dedication to to humanity’s quest for longer, healthier, happier lives through
innovation in pharmaceutical and health products
Product description

 SAMAR CCC is an antimicrobial resistance medicine
 Its is expected to replace antibiotics
 It is derived from two molecules
 Has undergone all phases of FDA approval
Industrial Analysis

 Pharmaceutical industry is worth over 650 billions
 90% of the industry is regulated
 Largest market is in North America
 Highest growth is experienced in European Union
Cont…
Market Needs

 Antibiotics are still essential
 There is fear of the growth of antimicrobial resistance medicine
 Antibiotics can be obtained over the counter
Trends and Challenges

 Antibiotics are known to have severe side effects
 Rise od antimicrobial medicine is threatening antibiotics
 Effective medical treatment can replace antibiotics
Competitive analysis

 Production of SAMAR CCC is less costly compared to the competition
 Less cost of FDA approval
 High chance of phase 1 and 2 approval waiver
Cont…
Strategy and implementation

 SAMAR CCC already patented in the U.S.
 Wide distribution channels for the drug
 Shortened marketing approval period
Marketing Plan

 Product will replace antibiotics
 Will be availed all over the globe
 Will cost low compared to other similar drugs
 Will be marketed using new technology
SWOT Analysis (Strengths)

 Wide distribution channel for the company
 Qualified and experienced team of scientists
 A team of marketing and sales professionals
 Own manufacturing plan
SWOT Analysis (Weaknesses,
Opportunities, and Threats)
 Weaknesses: High cost of production and being a private entity
 Opportunities: FDA approved, new markets, and use of technology
 Threats: Davos Declaration
Product Launch

 FDA Phases
 Phase 1: Assessing drug safety
 Phase 2: Testing efficacy of drug
 Phase 3: Determining benefits and effects
 Phase 4: Post marketing surveillance
Cont…

 Over the counter Phases
 Phase 1: Screening
 Phase 2: Preclinical pharmacology
 Phase 3: Preclinical safety
 Phase 4: Clinical pharmacology and safety
 Phase 5: Approval
Projected P & L
Projected 5-year Profit and Loss

"in Millions"

Year 1 Year 2 Year 3 Year 4 Year 5

Revenue 4510 5520 5610 5690 5740

Cost of Sales 3150 3690 4020 3810 3940

Gross profit/Loss 1360 1830 1590 1880 1800

Operating expenses 1060 1020 1200 960 840

Income/Loss 300 810 390 920 960
Projected Balance Sheet
Projected 5-year Balance Sheet

"in millions"
Year 1 Year 2 Year 3 Year 4 Year 5
Assets
Current Assets 30300 31310 26140 24920 25180

Fixed Assets 85000 85000 90000 92000 92000

Total Assets 115300 116310 116140 116920 117180
Liability and Shareholders Equity
Liabilities 65000 65500 65750 66000 66220

shareholders' equity 50000 50000 50000 50000 50000
Retained earnings 300 810 390 920 960

Total Liabilities and shareholder's equity 115300 116310 116140 116920 117180
Profitability chart

Biosantee Chem Profitability
1200

1000

800

600

400

200

0
1 2 3 4 5